Low biomass microbiota in the upper genital tract of reproductive age women: fact or fiction?

Thor Haahr, Jensen JS, Altmäe S, Peter Humaidan
Annals of clinical microbiology and antimicrobials · 2020 · doi:10.1186/s12941-020-00385-9 · PMID:32907604 · PMC7488088
OA: gold CC-BY-4.0
📄 Open PDF Full text JSON View on PubMed View at publisher
⚙ AI-generated summary by qwen3.7-flash+body, 2026-08-23 ⓘ

The provided text contains no scientific findings, as the opening of the body is marked "Not applicable" and consists solely of author contributions and conflict-of-interest disclosures.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

⚙ AI-generated deep summary by qwen3.7-flash, 2026-08-23 · read from full text ⓘ

The provided text consists entirely of author contributions, conflict of interest disclosures, and funding acknowledgments rather than the scientific content of the study. It details financial relationships with pharmaceutical companies such as Ferring, MSD, and Merck, as well as patent applications related to vaginal lactobacilli for in vitro fertilization success. The actual research methodology, results regarding upper genital tract microbiota, and conclusions are not present in the supplied excerpt. The paper does not explicitly discuss endometriosis or adenomyosis; it was included in the corpus via a keyword match in the upstream search index.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works

Full text 1,449 characters · extracted from epmc-fulltextxml · 9 sections · click to expand

Ack

Not applicable.

Ethics

Not applicable.

Consent

All authors have read and approved this manuscript for publication.

Funding

Not applicable.

Fn Group

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Competing

TH has received honoraria for lectures from Ferring, IBSA, Besins and Merck. PH received unrestricted research grants from MSD, Merck, and Ferring as well as honoraria for lectures from MSD, Merck, Gedeon-Richter, Theramex, and IBSA. JSJ has received speaker’s fee from Hologic, BD, SpeeDx, and Cepheid and serves scientific advisory board of Roche Molecular Systems, Abbott Molecular, and Cepheid. PH, TH and JSJ received an unrestricted research grant from Osel inc. which produces LACTIN-V, a live biotherapeutic product with Lactobacillus crispatus . PH and TH are listed as inventors in an international patent application (PCT/US2018/040882) involving “Use of vaginal lactobacilli for improving the success rate of in vitro fertilization”. SA reports funding and salary from The Spanish Ministry of Economy, Industry and Competitiveness (MINECO) and European Regional Development Fund (FEDER): grants RYC-2016-21199 and ENDORE SAF2017-87526-R; FEDER/Junta de Andalucía-Consejería de Economía y Conocimiento: MENDO (B-CTS-500-UGR18).

Authors’

TH drafted the manuscript. PH, JSJ and SA revised the manuscript. All authors read and approved the final manuscript.

Availability

Not applicable.

Associated Data

Not applicable.

Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy (via DOI) is the canonical version.

My notes (saved in your browser only)

⚙ Ask this paper AI returns verbatim quotes from the full text · source: epmc-fulltextxml ⓘ

Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. The paper's references may be in our DB but unresolved to ``paper_id`` (resolution happens at ingest when the cited DOI matches a row we already have). Run the cross-source citation reconcile pass to retry.

Source provenance

europepmc
last seen: 2026-10-04T09:26:46.659050+00:00
License: CC-BY-4.0 · commercial use OK · attribution required
Per Europe PMC